Related Experiment Video
Updated: Aug 1, 2026
06:19
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
[Clinical and experimental study on multiple sclerosis with bushen gusui tablet]
Summary
Bushen Gusui tablet (BSGS) shows therapeutic effects for multiple sclerosis (MS) patients and reduces experimental allergic encephalomyelitis (EAE) in guinea pigs. BSGS improves symptoms and reduces inflammation, indicating potential for clinical application.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Context:
- Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Experimental Allergic Encephalomyelitis (EAE) serves as a common animal model for studying MS pathogenesis and treatment.
- Traditional Chinese Medicine (TCM) offers potential therapeutic avenues for complex neurological disorders.
Purpose:
- To evaluate the efficacy of Bushen Gusui tablet (BSGS) in treating patients with Multiple Sclerosis (MS).
- To investigate the effects of BSGS on the Experimental Allergic Encephalomyelitis (EAE) model in guinea pigs.
- To assess the impact of BSGS on key immunological markers and neuropathological changes.
Summary:
- BSGS treatment in 43 MS patients resulted in improved clinical symptoms, reduced relapse frequency, and enhanced neurological function.
- In the EAE guinea pig model, high-dose BSGS significantly reduced disease incidence, inflammatory responses, and demyelination.
- BSGS administration inhibited serum levels of IL-2, IL-6, TNF, and MBP in EAE animals, comparable to prednisone acetate treatment.
Impact:
- The findings suggest BSGS possesses significant therapeutic potential for Multiple Sclerosis.
- BSGS demonstrates immunomodulatory and anti-inflammatory effects relevant to demyelinating diseases.
- Further clinical research and application of BSGS in managing MS are warranted.
